StreetInsider.com News Articles

Genmab reports Phase 2 response rate data for petosemtamab in mCRC

Sun, 25 Oct 2026 07:00:15 -0400

Genmab A/S (Nasdaq: GMAB) announced updated follow-up analyses from a Phase 2 trial of petosemtamab, an investigational bispecific antibody, in patients with metastatic colorectal cancer (mCRC). The findings were presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.

As of a May 15, 2026 data cutoff, 79 patients had been treated with petosemtamab in combination with FOLFOX or FOLFIRI chemotherapy — 45 in the first-line (1L) setting and 34 in the second-line (2L) setting. Among efficacy-evaluable patients, confirmed and unconfirmed objective response rates (ORRs) were 75% in 1L patients and 67% in 2L patients. In 1L patients

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Sun, 25 Oct 2026 07:00:00 -0400

Media Release

COPENHAGEN, Denmark; October 25, 2026

Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC)
Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients

Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Sun, 25 Oct 2026 07:00:00 -0400

Media Release

COPENHAGEN, Denmark; October 25, 2026

Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC)
Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients

Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.
“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.
“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.
“Metastatic colorectal cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Sat, 24 Oct 2026 07:00:00 -0400

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.
“Metastatic colorectal cancer

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics (NASDAQ: CORT)—which recently gained approval for its own rival platinum-resistant ovarian cancer treatment, Lifyorli (relacorilant)—fell 11% in contrasting sector movement.

The pivotal study met both its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS), delivering statistically significant and clinically meaningful improvements over investigator’s choice chemotherapy.

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics (NASDAQ: CORT)—which recently gained approval for its own rival platinum-resistant ovarian cancer treatment, Lifyorli (relacorilant)—fell 11% in contrasting sector movement.

The pivotal study met both its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS), delivering statistically significant and clinically meaningful improvements over investigator’s choice chemotherapy.

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics (NASDAQ: CORT)—which recently gained approval for its own rival platinum-resistant ovarian cancer treatment, Lifyorli (relacorilant)—fell 11% in contrasting sector movement.

The pivotal study met both its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS), delivering statistically significant and clinically meaningful improvements over investigator’s choice chemotherapy.

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics (NASDAQ: CORT)—which recently gained approval for its own rival platinum-resistant ovarian cancer treatment, Lifyorli (relacorilant)—fell 11% in contrasting sector movement.

The pivotal study met both its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS), delivering statistically significant and clinically meaningful improvements over investigator’s choice chemotherapy.

In the intent-to-treat population

Form 6-K GENMAB A/S For: Oct 23

Fri, 23 Oct 2026 11:59:00 -0400
si-local-file:///var/storage/secattach/20261023/27226814.html

Genmab's Rina-S meets phase 3 endpoints in ovarian cancer trial

Fri, 23 Oct 2026 11:56:11 -0400

Genmab A/S (Nasdaq: GMAB) announced positive topline results from its global Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
The trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) compared with investigator's choice chemotherapy, according to a company statement.
In the intent-to-treat population of 584 patients, Rina-S showed a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23–0.37; p<0.0001). In the primary analysis set of 492 patients, the drug showed a 67% reduction in that risk (HR

Genmab's Rina-S meets phase 3 endpoints in ovarian cancer trial

Fri, 23 Oct 2026 11:56:11 -0400

Genmab A/S (Nasdaq: GMAB) announced positive topline results from its global Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
The trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) compared with investigator's choice chemotherapy, according to a company statement.
In the intent-to-treat population of 584 patients, Rina-S showed a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23–0.37; p<0.0001). In the primary analysis set of 492 patients, the drug showed a 67% reduction in that risk (HR

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Fri, 23 Oct 2026 11:55:00 -0400

Company Announcement

COPENHAGEN, Denmark; October 23, 2026

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S^®) compared to investigator’s choice chemotherapy
Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)
Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S^®),

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Fri, 23 Oct 2026 11:55:00 -0400

Company Announcement

COPENHAGEN, Denmark; October 23, 2026

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S^®) compared to investigator’s choice chemotherapy
Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)
Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S^®),

Morgan Stanley Assumes Genmab A/S (GMAB) at Equalweight

Tue, 20 Oct 2026 03:15:40 -0400

Morgan Stanley analyst Sean Laaman assumes coverage on Genmab A/S (NASDAQ: GMAB) with a Equalweight rating and a price target of $42.00.
The analyst comments: “Genmab faces a fixed Darzalex royalty cliff, shifting the debate from whether the pipeline can replace lost revenue to how valuable those replacement dollars are. Darzalex contributed $2.44B, or ~65%, of FY25 revenue, with royalties ending in the US in 2029 and Europe/Japan in 2031. We model revenue peaking at ~$8.63B in FY30 before the cliff cuts it ~20% to ~$6.89B in FY31. We estimate the shortened royalty stream reduces FCF value by 10-21%, leaving a

Morgan Stanley Assumes Genmab A/S (GMAB) at Equalweight

Tue, 20 Oct 2026 03:15:40 -0400

Morgan Stanley analyst Sean Laaman assumes coverage on Genmab A/S (NASDAQ: GMAB) with a Equalweight rating and a price target of $42.00.
The analyst comments: “Genmab faces a fixed Darzalex royalty cliff, shifting the debate from whether the pipeline can replace lost revenue to how valuable those replacement dollars are. Darzalex contributed $2.44B, or ~65%, of FY25 revenue, with royalties ending in the US in 2029 and Europe/Japan in 2031. We model revenue peaking at ~$8.63B in FY30 before the cliff cuts it ~20% to ~$6.89B in FY31. We estimate the shortened royalty stream reduces FCF value by 10-21%, leaving a

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS

Wed, 14 Oct 2026 04:42:58 -0400
UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK3,100.00 (from DKK2,700.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS

Wed, 14 Oct 2026 04:42:58 -0400
UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK3,100.00 (from DKK2,700.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS

Wed, 14 Oct 2026 04:42:58 -0400
UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK3,100.00 (from DKK2,700.00) while maintaining a Buy rating.

Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS

Wed, 14 Oct 2026 04:42:58 -0400
UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK3,100.00 (from DKK2,700.00) while maintaining a Buy rating.

Form 6-K GENMAB A/S For: Oct 13

Tue, 13 Oct 2026 07:50:00 -0400
si-local-file:///var/storage/secattach/20261013/27177199.html

Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab

Tue, 13 Oct 2026 06:24:02 -0400

Genmab A/S (Nasdaq: GMAB) announced that worldwide net trade sales of DARZALEX (daratumumab) totaled $4,239 million in the third quarter of 2026, according to figures reported by Johnson & Johnson.
U.S. net trade sales reached $2,528 million, while sales in the rest of the world totaled $1,711 million. The figures include sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.
Genmab receives royalties on worldwide net sales of DARZALEX, covering both intravenous and subcutaneous products, under an exclusive worldwide license granted to Johnson & Johnson's legal entity Janssen Biotech, Inc. to develop, manufacture, and

Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab

Tue, 13 Oct 2026 06:24:02 -0400

Genmab A/S (Nasdaq: GMAB) announced that worldwide net trade sales of DARZALEX (daratumumab) totaled $4,239 million in the third quarter of 2026, according to figures reported by Johnson & Johnson.
U.S. net trade sales reached $2,528 million, while sales in the rest of the world totaled $1,711 million. The figures include sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.
Genmab receives royalties on worldwide net sales of DARZALEX, covering both intravenous and subcutaneous products, under an exclusive worldwide license granted to Johnson & Johnson's legal entity Janssen Biotech, Inc. to develop, manufacture, and